Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

3D models of human ERα and ERβ complexed with coumestrol.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Cortical lesion load associates with progression of disability in multiple sclerosis.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
Managing fatigue in patients with multiple sclerosis.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Immunology 2012
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.

Pages